ZANTE GREG (CIK 1264949) reported 10 SEC Form 4 insider transactions across 1 companies over the past 18 months (most recent 2026-01-05). Recent activity: Buy VKTX (41,000 shares), Buy VKTX (32,049 shares), Sell VKTX (31,961 shares), Sell VKTX (13,900 shares), Sell VKTX (10,300 shares). Source: SEC Form 4.
| Date | Company | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-01-05 | Viking Therapeutics, Inc. (VKTX) | Chief Financial Officer | Buy | 41,000 | $0 |
| 2026-01-05 | Viking Therapeutics, Inc. (VKTX) | Chief Financial Officer | Buy | 32,049 | $0 |
| 2026-01-05 | Viking Therapeutics, Inc. (VKTX) | Chief Financial Officer | Sell | 31,961 | $1.0M |
| 2026-01-05 | Viking Therapeutics, Inc. (VKTX) | Chief Financial Officer | Sell | 13,900 | $463,982 |
| 2026-01-05 | Viking Therapeutics, Inc. (VKTX) | Chief Financial Officer | Sell | 10,300 | $352,672 |
| 2026-01-05 | Viking Therapeutics, Inc. (VKTX) | Chief Financial Officer | Sell | 1,500 | $48,135 |
| 2025-10-28 | Viking Therapeutics, Inc. (VKTX) | Chief Financial Officer | Buy | 11,117 | $0 |
| 2025-10-28 | Viking Therapeutics, Inc. (VKTX) | Chief Financial Officer | Sell | 6,185 | $216,475 |
| 2025-07-03 | Viking Therapeutics, Inc. (VKTX) | Chief Financial Officer | Buy | 7,667 | $0 |
| 2025-07-03 | Viking Therapeutics, Inc. (VKTX) | Chief Financial Officer | Sell | 4,266 | $118,424 |
Source: SEC Form 4 filings · as of 2026-01-05